180 related articles for article (PubMed ID: 38733183)
1. [Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis].
Cai XB; Qu Y; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):303-305. PubMed ID: 38733183
[TBL] [Abstract][Full Text] [Related]
2. [Current status and challenges of clinical research and development of new drugs for liver diseases].
Shen ZY; Cai XB; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):289-294. PubMed ID: 38733180
[TBL] [Abstract][Full Text] [Related]
3. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.
Li H
J Ethnopharmacol; 2020 Apr; 251():112442. PubMed ID: 31891799
[TBL] [Abstract][Full Text] [Related]
4. The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.
Li J; Guo C; Wu J
Drug Des Devel Ther; 2021; 15():2619-2628. PubMed ID: 34168433
[TBL] [Abstract][Full Text] [Related]
5. Research Progress Regarding the Effect and Mechanism of Dietary Polyphenols in Liver Fibrosis.
Chang J; Huang C; Li S; Jiang X; Chang H; Li M
Molecules; 2023 Dec; 29(1):. PubMed ID: 38202710
[TBL] [Abstract][Full Text] [Related]
6. Emerging synthetic drugs for the treatment of liver cirrhosis.
Fallowfield JA; Jimenez-Ramos M; Robertson A
Expert Opin Emerg Drugs; 2021 Jun; 26(2):149-163. PubMed ID: 33856246
[No Abstract] [Full Text] [Related]
7. Progress in promising anti-fibrotic therapies.
Santoro R; Mangia A
Expert Rev Gastroenterol Hepatol; 2019 Dec; 13(12):1145-1152. PubMed ID: 31692390
[No Abstract] [Full Text] [Related]
8. [Treatment of liver fibrosis].
Domínguez M; Colmenero J; Bataller R
Gastroenterol Hepatol; 2009 Nov; 32(9):627-32. PubMed ID: 19647893
[TBL] [Abstract][Full Text] [Related]
9. Are we any closer to treating liver fibrosis (and if no, why not)?
Feng R; Yuan X; Shao C; Ding H; Liebe R; Weng HL
J Dig Dis; 2018 Mar; 19(3):118-126. PubMed ID: 29389083
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
11. Pathobiology of liver fibrosis: a translational success story.
Lee YA; Wallace MC; Friedman SL
Gut; 2015 May; 64(5):830-41. PubMed ID: 25681399
[TBL] [Abstract][Full Text] [Related]
12. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies.
Popov Y; Schuppan D
Hepatology; 2009 Oct; 50(4):1294-306. PubMed ID: 19711424
[TBL] [Abstract][Full Text] [Related]
13. Liver fibrosis: Common mechanisms and antifibrotic therapies.
Schuppan D
Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1():S51-9. PubMed ID: 26189980
[TBL] [Abstract][Full Text] [Related]
14. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
[TBL] [Abstract][Full Text] [Related]
15. Histological assessment based on liver biopsy: the value and challenges in NASH drug development.
Tong XF; Wang QY; Zhao XY; Sun YM; Wu XN; Yang LL; Lu ZZ; Ou XJ; Jia JD; You H
Acta Pharmacol Sin; 2022 May; 43(5):1200-1209. PubMed ID: 35165400
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive prediction of forthcoming cirrhosis-related complications.
Kang W; Kim SU; Ahn SH
World J Gastroenterol; 2014 Mar; 20(10):2613-23. PubMed ID: 24627597
[TBL] [Abstract][Full Text] [Related]
17. Determinants of fibrosis progression and regression in NASH.
Schuppan D; Surabattula R; Wang XY
J Hepatol; 2018 Feb; 68(2):238-250. PubMed ID: 29154966
[TBL] [Abstract][Full Text] [Related]
18. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.
Hauff P; Gottwald U; Ocker M
Expert Opin Investig Drugs; 2015 Mar; 24(3):309-27. PubMed ID: 25547844
[TBL] [Abstract][Full Text] [Related]
19. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis.
Shi YW; Fan JG
Acta Pharmacol Sin; 2022 May; 43(5):1191-1199. PubMed ID: 34907360
[TBL] [Abstract][Full Text] [Related]
20. [Present situation on non-invasive assessment of liver fibrosis/cirrhosis].
Zhang QD; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2018 May; 26(5):325-327. PubMed ID: 29996197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
